This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Medlab Clinical Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Medlab Clinical şirketinin toplam hissedar öz sermayesi A$7.7M ve toplam borcu A$0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla A$11.3M ve A$3.6M dir.

Anahtar bilgiler

Borç/özkaynak oranı

AU$0

Borç

Faiz karşılama oranı	n/a
Nakit	AU$5.54m
Eşitlik	AU$7.75m
Toplam yükümlülükler	AU$3.58m
Toplam varlıklar	AU$11.33m

Son finansal sağlık güncellemeleri

Is Medlab Clinical (ASX:MDC) In A Good Position To Invest In Growth?

Oct 05

Recent updates

Shareholders May Be More Conservative With Medlab Clinical Limited's (ASX:MDC) CEO Compensation For Now

Oct 06

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: MDC 'nin kısa vadeli varlıkları ( A$9.2M ) kısa vadeli yükümlülüklerini ( A$2.5M ) aşıyor.

Uzun Vadeli Yükümlülükler: MDC şirketinin kısa vadeli varlıkları ( A$9.2M ) uzun vadeli yükümlülüklerini ( A$1.1M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: MDC borçsuzdur.

Borcun Azaltılması: MDC şirketinin 5 yıl önce borç/öz sermaye oranı 9.7% iken borcu yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: MDC şirketinin mevcut serbest nakit akışına dayanarak yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

Tahmini Nakit Akışı: MDC tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

This company listing is no longer active

Medlab Clinical Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is Medlab Clinical (ASX:MDC) In A Good Position To Invest In Growth?

Recent updates

Consensus EPS estimates upgraded to AU$2.29 loss, revenue downgraded

Consensus forecasts updated

Price target decreased to AU$18.84

Medlab Announces Interim Readout of Rwe Medcare Study

Medlab Clinical Limited Receives UK Import Permission from MHRA for Nanabis

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Medlab Clinical Limited Provides NanoCelle Nasal RNA (Nucleid Acid) Program Update

Medlab Clinical Limited Provides NanaBis and NanoCBD Clinical Development Update

Less than half of directors are independent

Medlab Clinical Limited Announces the Resignation of Laurence McAllister as Non-Executive Director

Full year 2022 earnings: Revenues exceed analyst expectations

Medlab Clinical Limited, Annual General Meeting, Sep 30, 2022

Medlab Clinical Ltd Announces the European Patent Office Has Formalised ACCEPTANCE of the Depression Patent, and Within the Next 2-3 Months Will Be Granted

Medlab Clinical Limited Appoints Mohit Gupta as an Independent Non-Executive Director, Effective August 8, 2022

Medlab Clinical Ltd Updates Shareholders on the Progress of Our NanoCelle NanaBis Program

Medlab Clinical Ltd Announces Update on Progression of NanoCelle NASAL COVID-19 Vaccine Program

Less than half of directors are independent

Medlab Clinical Ltd Announces Update on NanoCBDTM

Medlab Clinical Ltd Announces the Receipt of "Favorable Opinion" Status from the UK Research Ethics Committee for the Forthcoming Nanabistm Phase 3 Trial, with No Additional Conditions or Submission Required

Shareholders May Be More Conservative With Medlab Clinical Limited's (ASX:MDC) CEO Compensation For Now

Is Medlab Clinical (ASX:MDC) In A Good Position To Invest In Growth?

Full year 2021 earnings released: AU$0.042 loss per share (vs AU$0.059 loss in FY 2020)

Medlab Receives Phase 3 NanaBi Trials Approval from the Australian Government, with Clinical Trials Number for Cancer Bone Pain

Australian Ethics Grants Approval for Medlab's NanaBisTM PIII Australian Sites

CFO, Company Secretary & COO has left the company

Medlab Clinical Limited announced that it expects to receive AUD 15 million in funding

Medlab Clinical Limited Appoints Cheryl Maley as an Independent Non-Executive Director

First half 2021 earnings released: AU$0.019 loss per share (vs AU$0.033 loss in 1H 2020)

What We Learned About Medlab Clinical's (ASX:MDC) CEO Pay

Medlab Executes Australian Exclusive Non-Binding Heads of Agreement with Arrotex Australia Group Australia Pty Ltd

Medlab Clinical Limited Receives Positive Depression Trial Prelim Results

New 90-day high: AU$0.36

Medlab Clinical Announces US FDA Grants Investigational New Drug (IND) Status for Nanabistm

Medlab Clinical (ASX:MDC) Share Prices Have Dropped 69% In The Last Three Years

Medlab Clinical Provides an Update on Clinical and Pre-Clinical Programs Currently Underway

Medlab Clinical Limited Announces NanaBis Observational Study Progression Report

New 90-day high: AU$0.26

Medlab Clinical Limited (ASX:MDC) Is Expected To Breakeven In The Near Future

Medlab Clinical Limited Announces NanaBisTM PIII Trial Launching in the Uk with Support from the National Institute for Health Research

New 90-day high: AU$0.21

Full year earnings released - AU$0.059 loss per share

Medlab Clinical Limited has completed a Follow-on Equity Offering in the amount of AUD 1.570476 million.

Medlab Clinical Limited announced that it has received AUD 5.397603 million in funding

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin